Dr Reddys Laboratories (RDY) Debt to Equity (2012 - 2026)

Dr Reddys Laboratories' Debt to Equity history runs 12 years deep, the most recent figure standing at $0.05 for Q1 2026.

• In Q1 2026, Debt to Equity fell 65.25% year-over-year to $0.05; the TTM figure through Mar 2026 stood at $0.05 (down 65.25% YoY), while the FY2026 annual figure was $0.05, up 84.75% from the prior year.
• Debt to Equity was $0.05 for Q1 2026 at Dr Reddys Laboratories, down from $0.14 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.14 in Q1 2025 to a low of $0.03 in Q1 2023.
• Historically, Debt to Equity has averaged $0.06 across 5 years, with a median of $0.05 in 2026.
• The sharpest annual moves came in 2024 and 2026: Debt to Equity jumped 153.33% in 2024, then slumped 65.25% in 2026.
• A 5-year view of Debt to Equity shows it stood at $0.04 in 2022, then slipped by 25.82% to $0.03 in 2023, then surged by 153.33% to $0.07 in 2024, then jumped by 106.45% to $0.14 in 2025, then plunged by 65.25% to $0.05 in 2026.
• The last three Debt to Equity figures came in at $0.05 (Q1 2026), $0.14 (Q1 2025), and $0.07 (Q1 2024), per Business Quant data.